Franklin Genomic Advancements ETF (HELX)
HELX is an actively managed ETF by Franklin Templeton. HELX launched on Feb 25, 2020 and has a 0.50% expense ratio.
ETF Info
| ISIN | US35473P5200 |
|---|---|
| CUSIP | 35473P520 |
| Issuer | Franklin Templeton |
| Inception Date | Feb 25, 2020 |
| Region | Developed Markets (Broad) |
| Category | Health & Biotech Equities, Actively Managed |
| Leveraged | 1x |
| Index Tracked | No Index (Active) |
| Asset Class | Equity |
Asset Class Size | Multi-Cap |
Asset Class Style | Growth |
Expense Ratio
HELX features an expense ratio of 0.50%, falling within the medium range.
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: HELX vs. BBH, HELX vs. BMEZ, HELX vs. FBT, HELX vs. IDNA, HELX vs. WDNA, HELX vs. IBB, HELX vs. ARKG, HELX vs. IBBQ, HELX vs. XBI, HELX vs. SOXX
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Franklin Genomic Advancements ETF, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Franklin Genomic Advancements ETF had a return of 3.48% year-to-date (YTD) and 20.90% in the last 12 months.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 3.48% | 25.70% |
| 1 month | -0.28% | 3.51% |
| 6 months | 1.21% | 14.80% |
| 1 year | 20.90% | 37.91% |
| 5 years (annualized) | N/A | 14.18% |
| 10 years (annualized) | N/A | 11.41% |
Monthly Returns
The table below presents the monthly returns of HELX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -2.26% | 7.99% | 1.86% | -8.22% | 3.24% | 2.07% | 6.17% | -1.06% | -2.61% | -6.77% | 3.48% | ||
| 2023 | 5.36% | -6.27% | 2.12% | -1.77% | -1.09% | 2.42% | 3.31% | -1.45% | -7.95% | -10.04% | 9.31% | 9.36% | 1.14% |
| 2022 | -19.37% | -3.80% | -1.88% | -11.81% | 2.46% | -3.95% | 10.57% | -9.41% | -7.59% | 4.30% | 3.31% | -5.72% | -37.89% |
| 2021 | 8.19% | -6.00% | -3.73% | 6.47% | -5.43% | 18.63% | 2.50% | 5.69% | -6.74% | 1.73% | -6.03% | -2.78% | 9.80% |
| 2020 | -6.65% | 18.17% | 12.23% | 3.63% | 11.13% | 3.89% | -1.07% | 1.22% | 12.97% | 10.43% | 85.05% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of HELX is 23, indicating that it is in the bottom 23% of ETFs on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Franklin Genomic Advancements ETF (HELX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Franklin Genomic Advancements ETF provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.
| Period | TTM | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Dividend | $0.00 | $0.00 | $0.00 | $0.12 | $0.05 |
Dividend yield | 0.00% | 0.00% | 0.00% | 0.24% | 0.12% |
Monthly Dividends
The table displays the monthly dividend distributions for Franklin Genomic Advancements ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.12 | $0.12 |
| 2020 | $0.05 | $0.05 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Franklin Genomic Advancements ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Franklin Genomic Advancements ETF was 56.33%, occurring on Oct 30, 2023. The portfolio has not yet recovered.
The current Franklin Genomic Advancements ETF drawdown is 45.72%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -56.33% | Sep 8, 2021 | 540 | Oct 30, 2023 | — | — | — |
| -27.15% | Mar 5, 2020 | 8 | Mar 16, 2020 | 25 | Apr 24, 2020 | 33 |
| -26.01% | Feb 16, 2021 | 15 | Mar 8, 2021 | 101 | Jul 30, 2021 | 116 |
| -8.87% | Sep 3, 2020 | 3 | Sep 8, 2020 | 19 | Oct 5, 2020 | 22 |
| -8.02% | Oct 14, 2020 | 14 | Nov 2, 2020 | 3 | Nov 5, 2020 | 17 |
Volatility
Volatility Chart
The current Franklin Genomic Advancements ETF volatility is 4.46%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.